Stephen Oesterle

Stephen Oesterle has held a variety of roles in numerous public and privately held companies since 2015. From 2015-2017, they were a Corporate Advisor for Temasek and a Health Care Consultant for numerous companies. From 2016-2017, they were a Board Director for Sigilon Therapeutics, Inc. and Alcyone Therapeutics Inc. In 2017, they joined Baxter International Inc. as a Board Director, where they chaired the Quality, Technology & Compliance Committee and was a member of the Governance Committee. In 2020, they became an Independent Non Executive Board Director for Peijia Medical (Suzhou) Co., Ltd and SHL Medical. In 2021, they were a Board Director for Paragon 28 and a Joint Steering Committee Member for G2 Bio Companies. Finally, in 2022, they became an Independent Board Director for CeramTec \u2013 The Ceramic Experts, where they chaired the Quality Committee and was a member of the Renumeration Committee.

Stephen Oesterle's education history includes a Bachelor of Arts (B.A.) in Chemistry from Harvard University, summa cum laude, obtained in 1973. Stephen then pursued a Doctor of Medicine (MD) from Yale University, which they obtained in 1977. Following this, they were a Post-doctoral Fellow at Harvard Medical School in Resident Internal Medicine at the Massachusetts General Hospital until 1980. In 1981, they became a Post Doctoral Fellow in Interventional Cardiology at Stanford University School of Medicine, which they completed in 1983. Additionally, in February 2020, Stephen Oesterle obtained a Certification in Cybersecurity Oversight from the National Association of Corporate Directors (NACD).